Human Astroviruses: A Tale of Two Strains.
HAstV-1
VA1
barrier permeability
human astrovirus
nitazoxanide
viral replication
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 02 2021
27 02 2021
Historique:
received:
04
02
2021
revised:
22
02
2021
accepted:
24
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
17
8
2021
Statut:
epublish
Résumé
Since the 1970s, eight closely related serotypes of classical human astroviruses (HAstV) have been associated with gastrointestinal illness worldwide. In the late 2000s, three genetically unique human astrovirus clades, VA1-VA3, VA2-VA4, and MLB, were described. While the exact disease associated with these clades remains to be defined, VA1 has been associated with central nervous system infections. The discovery that VA1 could be grown in cell culture, supports exciting new studies aimed at understanding viral pathogenesis. Given the association of VA1 with often lethal CNS infections, we tested its susceptibility to the antimicrobial drug, nitazoxanide (NTZ), which we showed could inhibit classical HAstV infections. Our studies demonstrate that NTZ inhibited VA1 replication in Caco2 cells even when added at 12 h post-infection, which is later than in HAstV-1 infection. These data led us to further probe VA1 replication kinetics and cellular responses to infection in Caco-2 cells in comparison to the well-studied HAstV-1 strain. Overall, our studies highlight that VA1 replicates more slowly than HAstV-1 and elicits significantly different cellular responses, including the inability to disrupt cellular junctions and barrier permeability.
Identifiants
pubmed: 33673521
pii: v13030376
doi: 10.3390/v13030376
pmc: PMC7997325
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Nitro Compounds
0
RNA, Viral
0
Thiazoles
0
nitazoxanide
SOA12P041N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI135254
Pays : United States
Références
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1450-6
pubmed: 10556104
PLoS One. 2011;6(8):e22576
pubmed: 21829634
Curr Protoc Microbiol. 2019 Feb;52(1):e73
pubmed: 30444308
J Genet Eng Biotechnol. 2020 Jul 28;18(1):35
pubmed: 32725286
J Clin Pathol. 2004 Sep;57(9):1001-3
pubmed: 15333670
J Clin Microbiol. 2002 Jan;40(1):133-9
pubmed: 11773106
J Clin Microbiol. 2004 Jan;42(1):151-7
pubmed: 14715746
J Virol. 2009 Oct;83(20):10836-9
pubmed: 19706703
J Clin Virol. 2020 Feb;123:104247
pubmed: 31864069
J Vet Diagn Invest. 2004 Jul;16(4):305-12
pubmed: 15305741
Emerg Infect Dis. 2010 Jun;16(6):918-25
pubmed: 20507741
PLoS One. 2011;6(12):e28647
pubmed: 22174853
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37
pubmed: 27322406
Bioinformatics. 2020 Oct 03;:
pubmed: 33010156
Cell Res. 2017 Aug;27(8):1046-1064
pubmed: 28685770
Clin Infect Dis. 2015 Mar 15;60(6):881-8
pubmed: 25572899
Virus Res. 2007 Nov;129(2):166-74
pubmed: 17714822
PLoS Pathog. 2019 Oct 31;15(10):e1008057
pubmed: 31671153
J Virol. 2015 Dec 09;90(5):2254-63
pubmed: 26656707
mBio. 2016 Nov 1;7(6):
pubmed: 27803180
Emerg Microbes Infect. 2016 Sep 07;5(9):e99
pubmed: 27599474
Viruses. 2017 Jan 22;9(1):
pubmed: 28117758
J Clin Microbiol. 2010 Dec;48(12):4392-6
pubmed: 20926705
J Virol. 2007 Nov;81(21):11937-45
pubmed: 17699569
mBio. 2019 Jul 9;10(4):
pubmed: 31289185
Virol J. 2008 Oct 14;5:117
pubmed: 18854035
Transbound Emerg Dis. 2017 Jun;64(3):677-682
pubmed: 28224712
Virol J. 2015 May 15;12:78
pubmed: 25975198
J Clin Virol. 2016 May;78:66-70
pubmed: 26991054
Lancet Infect Dis. 2014 Jul;14(7):609-18
pubmed: 24852376
J Infect. 2011 Nov;63(5):394-7
pubmed: 21839773
J Virol. 2003 Nov;77(21):11798-808
pubmed: 14557664
PLoS One. 2011;6(11):e27483
pubmed: 22096580
Clin Microbiol Infect. 2011 Jan;17(1):97-101
pubmed: 20219080
J Med Case Rep. 2019 Nov 23;13(1):341
pubmed: 31757225
Transpl Infect Dis. 2016 Dec;18(6):960-964
pubmed: 27632248
Clin Vaccine Immunol. 2014 Jun;21(6):908-11
pubmed: 24789796
Antiviral Res. 2014 Oct;110:94-103
pubmed: 25108173
Emerg Infect Dis. 2016 May;22(5):846-53
pubmed: 27088842
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1423-30
pubmed: 17081163
J Virol. 2017 Sep 12;91(19):
pubmed: 28701405
Viruses. 2017 Feb 18;9(2):
pubmed: 28218712
J Pediatric Infect Dis Soc. 2015 Sep;4(3):e53-7
pubmed: 26407445
Virol J. 2009 Oct 08;6:161
pubmed: 19814825
Pediatr Infect Dis J. 1999 Mar;18(3):249-54
pubmed: 10093946
J Med Microbiol. 1978 Nov;11(4):441-52
pubmed: 102800
Front Physiol. 2019 Jan 23;9:1942
pubmed: 30728783
Clin Diagn Lab Immunol. 1998 Jan;5(1):33-7
pubmed: 9455876
Clin Infect Dis. 2015 Mar 15;60(6):919-23
pubmed: 25572898
J Gen Virol. 1980 Jul;49(1):71-82
pubmed: 6775050
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
pubmed: 7984417
J Clin Virol. 2016 Sep;82:56-63
pubmed: 27434149
J Virol. 2020 Feb 14;94(5):
pubmed: 31776285
Cochrane Database Syst Rev. 2014 Apr 06;(4):CD009182
pubmed: 24706397
J Virol. 2008 Aug;82(15):7475-82
pubmed: 18508903
Epidemiol Infect. 1996 Aug;117(1):159-64
pubmed: 8760964